Clinical trials: Malignant Glioma of Brain
Brain and Central Nervous System Tumors
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006025
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- 9 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Central nervous system (CNS) malignancies are the second most common malignancy and the most common solid tumor of childhood, including adolescence.
- Conditions
- Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma
- Trial name
- NCT01884740
- Testing
- SIACI of Erbitux and Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Weill Medical College of Cornell University
Brain and Central Nervous System Tumors
Suramin in Treating Patients With Recurrent Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary…
- Trial name
- NCT00002639
- Testing
- chemotherapy, suramin
- Where
- United States
- Sponsor
- Emory University
Brain and Central Nervous System Tumors
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
Phase I/II trial to estimate the maximum tolerated dose of imatinib mesylate in newly diagnosed brain stem gliomas and recurrent high grade gliomas and to assess the effectiveness of imatinib mesylate in treating young patients…
- Trial name
- NCT00021229
- Testing
- imatinib mesylate, local irradiation therapy
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Brain Neoplasms, Primary Malignant
Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers
The purpose of this study is to explore the experiences and needs of patients with a high-grade glioma and their caregivers. Semi-structured interviews with patients and caregivers will be conducted and analysed using…
- Trial name
- NCT01638130
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent High-Grade Gliomas, Brain Neoplasm
A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.
SRN-101 is designed to destroys tumor cells while simultaneously activating the immune system to fight cancer. This is a first in human, single arm study to evaluate SRN-101 for the treatment of adults with recurrent high-grade…
- Conditions
- Recurrent High-Grade Gliomas, Brain Neoplasm, Glioma
- Trial name
- NCT07826949
- Testing
- SRN-101, Blood Specimen Collection, Surgical Resection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nicholas Butowski
Malignant Glioma
FMISO-PET in Brain Tumors and SCS Effect
The aim of this study is to assess, with 18F-FMISO PET, hypoxia in high grade gliomas and changes by spinal cord stimulation in a subset of patients.
- Trial name
- FMISOPETSCS (NCT01868906)
- Testing
- 18F-FMISO, PET without SCS, SCS
- Where
- 2 sites in Spain
- Volunteers
- 6 people
- Sponsor
- Bernardino Clavo, MD, PhD
Glioblastoma
Proteome-based Personalized Immunotherapy of Glioblastoma
Trial Hypothesis: Acute, progressing lethal neurooncological process can be transferred into chronic and non-lethal, the survival rates and life quality can be improved by of control of tumor cells (TCs) quantity and targeted…
- Trial name
- NCT01759810
- Testing
- Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- NeuroVita Clinic
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT00303940
- Testing
- carboplatin, talabostat mesylate, temozolomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Malignant Glioma
A Study of LY317615 in Patients With Brain Tumors
1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.
- Trial name
- NCT00190723
- Testing
- Enzastaurin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Brain and Central Nervous System Tumors
Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of immunotoxin therapy and to see how well it works in treating…
- Trial name
- NCT00053040
- Testing
- cintredekin besudotox, conventional surgery
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma, Anaplastic Astrocytoma
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade…
- Trial name
- NCT00431561
- Testing
- AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV
- Where
- 36 sites in Austria, Georgia and 4 more
- Volunteers
- 141 people
- Sponsor
- Isarna Therapeutics GmbH
Malignant Glioma of Brain
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
This human Phase I trial involves taking the patient's own tumor cells during surgical craniotomy, treating them with an investigational new drug (an antisense molecule) designed to shut down a targeted surface receptor protein…
- Trial name
- NCT01550523
- Testing
- IGF-1R/AS ODN, biodiffusion chamber
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Brain and Central Nervous System Tumors
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor.
- Trial name
- NCT00027625
- Testing
- gefitinib, temozolomide
- Where
- 11 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma, Glioblastoma
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
- Trial name
- NCT03551249
- Testing
- Focused ultrasound (FUS)
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
Brain and Central Nervous System Tumors
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00516282
- Testing
- CLORETAZINE, temozolomide
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme, Astrocytoma
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
This is a multicenter, open-label, continuation study to allow subjects who have previously received Toca 511 to continue to receive Toca FC and to allow for extended safety observations.
- Conditions
- Glioblastoma Multiforme, Astrocytoma, Gliomas, Malignant
- Trial name
- NCT04327011
- Testing
- Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Tocagen Inc.
Brain and Central Nervous System Tumors
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus carmustine in treating patients who have…
- Trial name
- NCT00002988
- Testing
- carmustine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
This is a multicenter study evaluating the safety and tolerability of Toca 511 administered intravenously to patients with recurrent or progressive Grade III or Grade IV Gliomas who have elected to undergo surgical removal of…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01985256
- Testing
- Toca 511, Toca FC
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Tocagen Inc.